Biotech »

RepliCel joins MedCision’s ThawStar program

RepliCel joins MedCision’s ThawStar program

Alpha Stox August 16, 2017 0

Mr. R. Lee Buckler reports REPLICEL LIFE SCIENCES JOINS MEDCISION’S THAWSTAR EARLY ADOPTER PROGRAM RepliCel Life Sciences Inc. has joined MedCision’s ThawStar early adopter program, a novel program that helps companies and investigators derisk

Read More »
Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease

Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease

Alpha Stox August 14, 2017 0

SAN FRANCISCO and TEL AVIV, Israel, Aug. 14, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today announced that it

Read More »
SQI, McMaster to develop chip tech for disease testing

SQI, McMaster to develop chip tech for disease testing

Alpha Stox July 24, 2017 Comments Off

Mr. Andrew Morris reports SQI PARTNERS WITH MCMASTER TO CO-DEVELOP “INSTANT IMMUNOASSAY” TESTING TECHNOLOGY SQI Diagnostics Inc. has signed a technology development partnership and licensing agreement with the McMaster University’s department of engineering to

Read More »
Ventripoint appoints Hirson as development VP

Ventripoint appoints Hirson as development VP

Alpha Stox July 20, 2017 Comments Off

Dr. George Adams reports A THIRD HIGHLY SUCCESSFUL ULTRASOUND EXECUTIVE JOINS VENTRIPOINT Ventripoint Diagnostics Ltd. has appointed Desmond Hirson as vice-president, development and operations. “The Ventripoint technology brings a much needed application to cardiac

Read More »
Resverlogix’s BETonMACE trial gets fourth positive rec

Resverlogix’s BETonMACE trial gets fourth positive rec

Alpha Stox June 28, 2017 Comments Off

Dr. Michael Sweeney reports RESVERLOGIX ANNOUNCES FOURTH POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD FOR PHASE 3 STUDY OF APABETALONE The independent data and safety monitoring board (DSMB) for Resverlogix Corp.’s phase 3 BETonMACE

Read More »
Kalytera’s Salzman quits as CEO, CMO, director

Kalytera’s Salzman quits as CEO, CMO, director

Alpha Stox June 22, 2017 Comments Off

Mr. Robert Farrell reports KALYTERA ANNOUNCES MANAGEMENT CHANGES AND EXPANSION OF LEADERSHIP TEAM Dr. Andrew L. Salzman, MD, who previously served as Kalytera Therapeutics Inc.’s chief executive officer and chief medical officer, and as

Read More »
BELLUS Health announces sale of its equity interest in FB Health for total consideration up to CA$2.5M

BELLUS Health announces sale of its equity interest in FB Health for total consideration up to CA$2.5M

Alpha Stox June 19, 2017 Comments Off

LAVAL, QC, June 19, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced the sale of its equity interest

Read More »
RepliCel Life, UBC to perform hair follicle study

RepliCel Life, UBC to perform hair follicle study

Alpha Stox June 13, 2017 Comments Off

Mr. Lee Buckler reports REPLICEL COLLABORATES WITH UNIVERSITY OF BRITISH COLUMBIA TO BUILD WORLD-CLASS HAIR FOLLICLE CELL DATA MAP RepliCel Life Sciences Inc. has signed a collaborative research project agreement with the University of

Read More »
Kane Biotech arranges $4-million placement

Kane Biotech arranges $4-million placement

Alpha Stox June 1, 2017 Comments Off

Mr. Mark Ahrens-Townsend reports KANE BIOTECH ANNOUNCES PRIVATE PLACEMENT OFFERING Kane Biotech Inc. intends to undertake a non-brokered private placement offering of up to 33,333,333 units at a price of 12 cents per unit

Read More »
Revive, UW Madison enter cannabinoid research agreement

Revive, UW Madison enter cannabinoid research agreement

Alpha Stox May 30, 2017 Comments Off

Mr. Craig Leon reports REVIVE THERAPEUTICS ANNOUNCES SPONSORED RESEARCH AGREEMENT WITH THE UNIVERSITY OF WISCONSIN-MADISON TO EVALUATE A NOVEL DRUG DELIVERY TECHNOLOGY FOCUSED ON CANNABINOIDS Revive Therapeutics Ltd. has entered into a sponsored research

Read More »
Newsletterpopup_top_1

Your Name (required)

Your Email (required)

captcha

Newsletterpopup_bottom_1